Radioiodinated antibody targeting of the HER-2/neu oncoprotein

F. J. Xu, Y. H. Yu, D. S. Bae, X. G. Zhao, S. K. Slade, C. M. Boyer, Robert C. Bast, M. R. Zalutsky

Research output: Contribution to journalArticle

21 Scopus citations


The HER-2/neu oncogene encodes a 185 kDa phosphoglycoprotein that is overexpressed in breast, ovarian and other cancers. Seven monoclonal antibodies reactive with this oncoprotein were labeled with 131I. In vitro experiments with SKOv3 9002-18 cells determined binding affinity, internalization and degradation. The biodistribution of these antibodies in comparison to 125I-labeled nonspecific antibody was measured in athymic mice with SKOv3 9002-18 ovarian carcinoma xenografts. Antibody 520C9 exhibited the highest and most specific retention in tumor, peaking at 17.4 ± 5.6% ID/g at 24 h.

Original languageEnglish (US)
Pages (from-to)451-459
Number of pages9
JournalNuclear Medicine and Biology
Issue number5
StatePublished - Jul 1997


  • C-erbB-2 (HER-2/neu)
  • Monoclonal antibody
  • Ovarian cancer
  • Radioiodination
  • Tumor

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Radioiodinated antibody targeting of the HER-2/neu oncoprotein'. Together they form a unique fingerprint.

  • Cite this

    Xu, F. J., Yu, Y. H., Bae, D. S., Zhao, X. G., Slade, S. K., Boyer, C. M., Bast, R. C., & Zalutsky, M. R. (1997). Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nuclear Medicine and Biology, 24(5), 451-459.